New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:21 EDTMRK, BAXMerck names Robert Davis as CFO, effective April 23
Merck (MRK) announced the appointment of Robert M. Davis as executive vice president and CFO, effective April 23, 2014. Davis, who will also oversee corporate strategy and corporate business development, will succeed Peter N. Kellogg. Kellogg will work closely with Davis to ensure a seamless transition and will leave Merck on May 16. Davis is corporate vice president and president of Baxter’s (BAX) Medical Products business.
News For MRK;BAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 21, 2014
06:29 EDTBAXBaxter management to meet with Leerink
Subscribe for More Information
October 20, 2014
09:04 EDTBAXBaxter, Halozyme launch HYQVIA in U.S.
Subscribe for More Information
08:06 EDTMRKMerck, Sanofi unit announce pediatric hexavalent vaccine BLA
Subscribe for More Information
07:34 EDTMRKAdvaxis names Mauro Chief Medical Officer
Advaxis (ADXS) announced that it has appointed David Mauro, as executive vice president, Chief Medical Officer Mauro most recently served as executive director, section head oncology clinical development at Merck (MRK). In connection with his appointment, Mauro received a one-time inducement award of 165K restricted shares, of which 55K are fully vested and as of the grant date. The remaining shares vest annually over a two-year period.
07:19 EDTMRKIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTMRKAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
October 17, 2014
07:58 EDTMRKDeutsche Bank specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Gilbert provides of preview of The Improved Reduction of Outcomes: Vytorin Efficacy Internal Study (IMPROVE-IT) on an Analyst/Industry conference call to be held on October 17 at 10 am.
October 16, 2014
09:04 EDTBAXBaxter says spin-off of BioScience division on track for mid-2015 completion
Subscribe for More Information
09:02 EDTBAXBaxter says it still has not experienced competition for cyclophosphamide
Subscribe for More Information
08:38 EDTBAXBaxter expects divestiture of vaccines business to Pfizer to close in Q4
Subscribe for More Information
07:03 EDTBAXBaxter sees FY14 continuing ops EPS $4.86-$4.89, consensus $5.16
Subscribe for More Information
07:02 EDTBAXBaxter sees Q4 continuing ops EPS $1.30-$1.33, consensus $1.41
Sees Q4 sales growth approx. 3% excluding the impact of foreign currency. Including the impact of foreign currency, the company expects reported sales to be flat to 2013 levels. Consensus is $4.39B.
07:01 EDTBAXBaxter reports Q3 adjusted EPS $1.35, consensus $1.31
Reports Q3 revenue $4.2B, consensus $4.2B.
October 15, 2014
15:28 EDTBAXNotable companies reporting before tomorrow's open
Subscribe for More Information
12:42 EDTMRKNY AG announces $31M Medicaid settlement with Organon
Subscribe for More Information
09:57 EDTMRKLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 14, 2014
11:23 EDTMRKBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
07:15 EDTBAXBaxter October volatility elevated into Q3 and guidance
Baxter October option implied volatility is at 33, November is at 23, December is at 19, February is at of 17; compared to its 26-week average of 18 according to Track Data, suggesting large near term price movement into the expected release of Q3 results on October 16.
October 13, 2014
07:37 EDTMRK, BAXAmerican Society of Anesthesiologists to hold annual meeting
Subscribe for More Information
07:25 EDTBAXEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use